Safety and Efficacy of Liposomal Amphotericin B Compared with Conventional Amphotericin B for Induction Therapy of Histoplasmosis
in Patients with AIDS
- Philip C. Johnson, MD;
- L. Joseph Wheat, MD;
- Gretchen A. Cloud, MS;
- Mitchell Goldman, MD;
- Dan Lancaster, MD;
- David M. Bamberger, MD;
- William G. Powderly, MD;
- Richard Hafner, MD;
- Carol A. Kauffman, MD;
- William E. Dismukes, MD; and
- for the U.S. National Institute of Allergy and Infectious Diseases Mycoses Study Group*
-
From the University of Texas–Houston Medical School, Houston, Texas; Indiana University School of Medicine and Roudebush Veterans
Affairs Medical Center, Indianapolis, Indiana; University of Alabama at Birmingham, Birmingham, Alabama; Methodist Hospital,
Memphis, Tennessee; University of Missouri–Kansas City, Kansas City, and Washington University School of Medicine, St. Louis,
Missouri; National Institute of Allergy and Infectious Diseases Mycoses Study Group, National Institutes of Health, Bethesda,
Maryland; and Veterans Affairs Medical Center and University of Michigan Medical School, Ann Arbor, Michigan.
-
Figure 1. Flow of patients through the study.
-
Figure 2. . Time to clinical response, as defined by defervescence, for patients with a temperature higher than 37.8 °C 1
day before or at baseline. value for clinical response, defined by defervescence, was 0.09 using the log-rank test. . Survival
during induction therapy. value for survival during induction therapy was 0.04 using the log-rank test. Kaplan–Meier analysis.TopPBottomP
- Copyright ©2004 by the American College of Physicians
-
Ann Intern Med
July 16, 2002
vol. 137
no. 2
105-109